MetaVia Inc. — Director's Dealing 2016

Aug 5, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04

Reporting Person: Gullans Steven R. Ph.D. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
8% Convertible Subordinated Promissory Note	$6.7059		Common Stock ()		Indirect

Footnotes

F1: The note was issued in the original principal amount of $2,000,000. The outstanding principal and accrued interest on such note will automatically convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") immediately prior to the closing of the Company's initial public offering. The note bears interest at a rate of 8% per annum. The note has accrued interest of $49,534 to date and will continue to accrue interest until conversion.

F2: The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.